Guggenheim Capital’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-23,601
| Closed | -$564K | – | 2274 |
|
|
2021
Q1 | $564K | Buy |
+23,601
| New | +$439K | ﹤0.01% | 1662 |
|
|
2017
Q1 | – | Sell |
-10,694
| Closed | -$131K | – | 2958 |
|
|
2016
Q4 | $131K | Buy |
10,694
+39
| +0.4% | +$463 | ﹤0.01% | 2744 |
|
|
2016
Q3 | $126K | Sell |
10,655
-3
| -0% | -$29 | ﹤0.01% | 2709 |
|
|
2016
Q2 | $92K | Buy |
10,658
+358
| +3% | +$2.45K | ﹤0.01% | 2733 |
|
|
2016
Q1 | $54K | Buy |
+10,300
| New | +$57.3K | ﹤0.01% | 2797 |
|
|
2014
Q3 | – | Sell |
-16,884
| Closed | -$228K | – | 3168 |
|
|
2014
Q2 | $228K | Sell |
16,884
-1,660
| -9% | -$17.3K | ﹤0.01% | 2859 |
|
|
2014
Q1 | $184K | Buy |
18,544
+3,299
| +22% | +$41K | ﹤0.01% | 2907 |
|
|
2013
Q4 | $203K | Buy |
15,245
+1,155
| +8% | +$14K | ﹤0.01% | 2840 |
|
|
2013
Q3 | $171K | Buy |
14,090
+4,026
| +40% | +$43.2K | ﹤0.01% | 2756 |
|
|
2013
Q2 | $104K | Buy |
+10,064
| New | +$139K | ﹤0.01% | 2822 |
|
Guggenheim Capital's GNMK Position: Q2 2021 in Review
Guggenheim Capital sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 23,601 shares — an estimated $564K sold.
Guggenheim Capital first reported a position in GNMK in Q2 2013 and held it in 10 quarters. The position peaked at $564K in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Guggenheim Capital reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Guggenheim Capital sold 23,601 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $564K.
- Guggenheim Capital first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 10 quarters.
- Guggenheim Capital's GenMark Diagnostics, Inc position peaked at $564K in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Guggenheim Capital's 13F filing for Q2 2021, filed 13 Aug 2021.